[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338263-105":59,"doc-detail-338263-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","car-t-cell-therapy-advances-in-digestive-system-malignant-tumors","CAR-T cell therapy - Advances in digestive system malignant tumors","","Malignant tumors of the digestive system have historically shown poor outcomes, with high recurrence and metastasis rates despite surgery, chemotherapy, radiotherapy, and immunotherapy. CAR-T therapy has produced promising antitumor activity in hematologic cancers, yet its efficacy and safety in digestive system tumors remain limited by weak targeting, impaired infiltration into solid tumors, and short in vivo survival. The paper summarizes developments, obstacles, and countermeasures, emphasizing antigen target regulation, tumor microenvironment effects, and immune evasion mechanisms to support further CAR-T-based research.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/car-t-cell-therapy-advances-in-digestive-system-malignant-tumors/338263/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/car-t-cell-therapy-advances-in-digestive-system-malignant-tumors/338263.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are digestive system malignant tumors difficult to treat?","Question",{"text":112,"@type":113},"They have historically poor prognoses, with high recurrence and metastasis rates. Conventional therapies still leave significant mortality and limited effectiveness in advanced disease.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limits the clinical translation of CAR-T therapy for digestive system cancers?",{"text":117,"@type":113},"Ineffective antitumor effects and adverse effects persist, alongside challenges such as restricted protein targeting, poor CAR-T infiltration into solid tumors, and limited survival time in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"Which aspects does the analysis emphasize for improving CAR-T therapy?",{"text":121,"@type":113},"It focuses on the regulatory functions of potential antigen targets, the tumor microenvironment, and immune evasion during CAR-T treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338263,1790810559,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","CAR-T cell therapy: Advances  \nin digestive system malignant tumors  \nNan Xu, 1,2,5 Zhonglin Wu,2,5 Jun Pan, 1,5 Xiao Xu,3,4 and Qiang Wei3  \n1Zhejiang University School of Medicine, Hangzhou 310058, China; 2Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Afﬁliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou 310006, China; 3School of Clinical Medicine, Hangzhou Medical College, Hangzhou 310053, China; 4Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, China  \nMalignant tumors of the digestive system have had a notoriously dismal prognosis throughout history. Immunotherapy, radiotherapy, surgery, and chemotherapy are the primary therapeutic approaches for digestive system cancers. The rate of recurrence and metastasis, nevertheless, remains elevated. As one of the immunotherapies, chimeric antigen receptor T cell (CAR-T) therapy has demonstrated a promising antitumor effect in hematologic cancer. Despite undergoing numerous clinical trials, the ineffective antitumor effect and adverse effects of CAR-T cell therapy in the treatment of digestive system cancers continue to impede its clinical translation. It is necessary to surmount the restricted options for targeting proteins, the obstacles that impede CAR-T cell inﬁltration into solid tumors, and the limited survival time in vivo. We examined and summarized the developments, obstacles, and countermeasures associated with CAR-T therapy in digestive system cancers. Emphasis was placed on the regulatory functions of potential antigen targets, the tumor microenvironment, and immune evasion in CAR-T therapy. Thus, our analysis has furnished an all-encompassing comprehension of CAR-T cell therapy in digestive system cancers, which will generate tremendous enthusiasm for subsequent in-depth research into CAR-Tbased therapies in digestive system cancers.  \nINTRODUCTION  \nMalignant tumors ofthe digestive system refer to a range of malignant tumors that occur in the digestive tracts and some associated organs.1 The primary categories of digestive system cancer are esophageal cancer, gastric cancer (GC), colorectal cancer (CRC), liver cancer, pancreatic cancer, and gallbladder cancer.2 Based on data from Global Cancer Observatory statistics (GLOBOCAN), CRC has the thirdhighest occurrence rate among all types of cancer (10.2%) in both males and females.3–5 It also has the highest rate among all digestive system cancers, followed by GC (5.7%; ranked 6th among all cancers), liver cancer (4.7%; ranked 7th among all cancers), esophageal cancer (3.2%; ranked 8th among all cancers), and pancreatic cancer (2.5%; ranked 13th among all cancers) .3–5 CRC has the second-highest fatality rate among all types of cancer (9.2%), and the highest fatality rate among all digestive system cancers, followed by liver cancer (8.2%), stomach cancer (8.2%), esophageal cancer (5.3%; ranking 6th among all cancers), and pancreatic cancer (4.5%; ranking 7th among all can-  \ncers) .3–5 The primary modalities utilized for digestive system cancer treatment are surgical intervention, chemotherapeutic agents, and immunotherapeutic approaches.3–6 However, it continues to have asigniﬁcant mortality rate. For instance, in the case ofCRC, 20% of individuals with CRC are identiﬁed at stage V, which has a 5-year relative survival rate of 12 .5% .7 For individuals with metastatic CRC, treatment options other than for liver and lung metastasis primarily consist of palliative measures such as systemic chemotherapy and supportive therapy. Their lifespan typically does not exceed 12 months.8 Tumors affecting the digestive system, such as those in the bile ducts, pancreas, and stomach, are highly malignant and have limited success with conventional treatments.  \nThe chimeric antigen receptor (CAR) is a modular fusion protein that typically consists of a co-stimulatory molecule derived from an antibody single-chain ","cbCaioJytYmpEUdy","https://ap.wps.com/l/cbCaioJytYmpEUdy","pdf",2161046,13,"English","# Introduction\n## Digestive system cancer overview and clinical burden\n## CAR-T structure and mechanism of action\n## CAR-T progress and challenges in solid tumors","[{\"question\":\"Why are digestive system malignant tumors difficult to treat?\",\"answer\":\"They have historically poor prognoses, with high recurrence and metastasis rates. Conventional therapies still leave significant mortality and limited effectiveness in advanced disease.\"},{\"question\":\"What limits the clinical translation of CAR-T therapy for digestive system cancers?\",\"answer\":\"Ineffective antitumor effects and adverse effects persist, alongside challenges such as restricted protein targeting, poor CAR-T infiltration into solid tumors, and limited survival time in vivo.\"},{\"question\":\"Which aspects does the analysis emphasize for improving CAR-T therapy?\",\"answer\":\"It focuses on the regulatory functions of potential antigen targets, the tumor microenvironment, and immune evasion during CAR-T treatment.\"}]","CAR-T cell therapy - Advances in digestive system malignant tumors | PDF",1790022824,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7aa859dfb9a7ecf33ba77d276debe29.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b852e96c1f1fd88aff9c4ff2ac4f3924.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73c3dee116479b077fe04dc68a6152cc.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2eb0d9eeeef17a9decc3364aefd0e341.webp",980,1272]